<code id='59C2AAA725'></code><style id='59C2AAA725'></style>
    • <acronym id='59C2AAA725'></acronym>
      <center id='59C2AAA725'><center id='59C2AAA725'><tfoot id='59C2AAA725'></tfoot></center><abbr id='59C2AAA725'><dir id='59C2AAA725'><tfoot id='59C2AAA725'></tfoot><noframes id='59C2AAA725'>

    • <optgroup id='59C2AAA725'><strike id='59C2AAA725'><sup id='59C2AAA725'></sup></strike><code id='59C2AAA725'></code></optgroup>
        1. <b id='59C2AAA725'><label id='59C2AAA725'><select id='59C2AAA725'><dt id='59C2AAA725'><span id='59C2AAA725'></span></dt></select></label></b><u id='59C2AAA725'></u>
          <i id='59C2AAA725'><strike id='59C2AAA725'><tt id='59C2AAA725'><pre id='59C2AAA725'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:fashion    Page View:883
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In